Abstracts tagged "corticosteroids"

Abstract Number: 1833 • 2015 ACR/ARHP Annual Meeting
Musculoskeletal Complications of Systemic Lupus Erythematosus: Risk Factors for and Prevalence of Avascular Necrosis and Osteoporosis
Maeve Gamble¹ and Janet E. Pope², ¹Medicine, University of Western Ontario, London, ON, Canada, ²University of Western Ontario, London, ON, Canada
Background/Purpose: Osteoporosis (OP) and avascular necrosis (AVN) are well-recognized musculoskeletal complications of systemic lupus erythematosus (SLE) and cause morbidity. Steroid therapy and the underlying disease…
Abstract Number: 1979 • 2015 ACR/ARHP Annual Meeting
Baseline Data on Patients Enrolled in a Randomized, Double-Blind Trial of Tocilizumab in Giant Cell Arteritis
Katie Tuckwell¹, Neil Collinson¹, Micki Klearman², Sophie Dimonaco¹, John H. Stone³ and on behalf of the GiACTA Investigators, ¹Roche Products Ltd., Welwyn Garden City, United Kingdom, ²Genentech, South San Francisco, CA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: GiACTA, a randomized, double-blind, placebo-controlled trial of the interleukin-6 receptor alpha inhibitor tocilizumab (TCZ) in patients (pts) with giant cell arteritis (GCA), is the…
Abstract Number: 2778 • 2014 ACR/ARHP Annual Meeting
Non-Systemic Vasculitic Neuropathy: Presentation, Therapeutic Management and Outcome
Benjamin Terrier¹, Fleur Cohen², Aude Rigolet³, Jean-Emmanuel Kahn⁴, Alice Berezne⁵, Olivier Benveniste⁶, Alain Créange⁷, Thierry Maisonobe⁸, Zahir Amoura⁹, Luc Mouthon¹⁰ and Loïc Guillevin for the French Vasculitis Study Group¹⁰, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²Internal Medicine, Pitié-Salpétrière, Paris, France, ³Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, ⁴Internal Medicine, Foch Hospital, Suresnes, France, ⁵Paris Descartes University, Internal Medicine department, Cochin Hospital, Paris, France, ⁶UMR 974, Sorbonne Universités, University Pierre et Marie-Curie-Paris 6, INSERM, Paris, France, ⁷Neurology, Henri Mondor, Créteil, France, ⁸Neuropathology, Pitie-Salpetriere Hospital, Paris, France, ⁹Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ¹⁰National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France
Background/Purpose Non-systemic vasculitic neuropathy (NSVN) is a small-to-medium–sized vessel vasculitis limited to the peripheral nervous system. It can be considered a single-organ vasculitis, as recently…
Abstract Number: 1857 • 2014 ACR/ARHP Annual Meeting
Determinants of Annual Healthcare Utilization and Overall Cost of Care in Individuals with Systemic Lupus Erythematosus in a Large Insurance Claims Database: Glucocorticoid Use
Shih-Yin Chen¹, Chan-Bum Choi^2,3,4, Qian Li⁵, Wei-Shi Yeh¹, Yuan-Chi Lee⁶, Amy H Kao¹ and Matthew H. Liang⁷, ¹Biogen Idec, Cambridge, MA, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Section of Rheumatology, VA Healthcare System, Boston, MA, ⁴Department of Aging, Brigham and Women's Hospital, Boston, MA, ⁵Evidera, Lexington, MA, ⁶Formerly of Evidera, Lexington, MA, ⁷Harvard Medical School, Boston, MA
Background/Purpose: Newer therapeutic agents in systemic lupus erythematosus (SLE) may increase cost of care but their effect on limiting the duration and the dosage of…
Abstract Number: 1397 • 2014 ACR/ARHP Annual Meeting
Impact of Corticosteroid Use on Remission Sustainability and Infection Rates Among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on a Real-World Canadian Population
Boulos Haraoui¹, Algis Jovaisas², William G. Bensen³, Rafat Faraawi⁴, John Kelsall⁵, Sanjay Dixit⁴, Jude Rodrigues⁶, Maqbool Sheriff⁷, Emmanouil Rampakakis⁸, John S. Sampalis⁸, Allen J Lehman⁹, Susan Otawa⁹, Francois Nantel¹⁰ and May Shawi¹⁰, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁶Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada
Background/Purpose The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…
Abstract Number: 1252 • 2014 ACR/ARHP Annual Meeting
Intravenous Methylprednisolone Pulse Therapy in Severe Inflammatory Eye Disease. a Multicenter Study
Montserrat Santos-Gómez¹, Emma Beltrán², Vanesa Calvo-Río¹, Ricardo Blanco¹, Norberto Ortego³, Jose L. García Serrano⁴, Lucía Martínez Costa⁴, Alejandro Fonollosa⁵, Marisa Hernández⁶, Elia Valls⁷, Félix Francisco⁸, Miguel A. Reyes⁹, Ignacio Torre Salaberri¹⁰, Olga Maíz¹¹, Ana Blanco¹², Santiago Muñoz-Fernández¹³, M. Mar Esteban¹⁴, Esperanza Pato¹⁵, Manuel Díaz-Llopis¹⁶, Roberto Gallego¹⁶, Miguel Cordero¹⁷, Francisco Ortiz-Sanjuán¹, Joaquín Cañal Villanueva¹⁸, Leyre Riancho-Zarrabeitia¹ and Miguel A González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ³Autoimmune Disease Unit, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ⁴Ophthalmology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ⁵Ophthalmology, Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, ⁶Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁷Rheumatology, Hospital Dr. Peset. Valencia. Spain, Valencia, Spain, ⁸Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, ⁹Ophthalmology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, ¹⁰Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ¹¹Rheumatology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, ¹²Ophthalmology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, ¹³Rheumatology, Hospital Infanta Sofía. San Sebastián de los Reyes. Spain, Madrid, Spain, ¹⁴Ophthalmology, Hospital Infanta Sofía. San Sebastián de los Reyes. Spain, Madrid, Spain, ¹⁵Rheumatology, Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, ¹⁶Ophthalmology, Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ¹⁷Ophthalmology, Hospital de León. Spain, León, Spain, ¹⁸Ophthalmology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Intravenous methylprednisolone pulse therapy in severe inflammatory eye disease. A Multicenter Study.Background/Purpose Treatment with high-dose intravenous methylprednisolone (IVMP) pulse therapy has proved to be effective…
Abstract Number: 1235 • 2014 ACR/ARHP Annual Meeting
Recovery of Renal Function after Corticosteroid Therapy for IgG4-Related Kidney Disease
Takako Saeki¹, Mitsuhiro Kawano², Ichiro Mizushima², Motohisa Yamamoto³, Yoshifumi Ubara⁴, Hitoshi Nakashima⁵, Yoko Wada⁶, Tomoyuki Ito⁷, Hajime Yamazaki⁷, Ichiei Narita⁶ and Takao Saito^5,8, ¹Department of Internal Medicine, Nagaoka Red Cross Hospital, Nagaoka, Japan, ²Kanazawa University Hospital, Kanazawa, Japan, ³Sapporo Medical University School of Medicine, Sapporo, Japan, ⁴Toranomon Hospital, Tokyo, Japan, ⁵Div of Nephrol & Rheumatol, Dept of Int Med, Faculty of Medicine, Fukuoka University, Fukuoka, Japan, ⁶Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ⁷Nagaoka Red Cross Hospital, Nagaoka, Japan, ⁸General Medical Research Center, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
Background/Purpose: In our earlier study of IgG4-related kidney disease (IgG4-RKD), we found that renal dysfunction, which was mostly attributable to IgG4-related tubulointerstitial nephritis, was significantly…
Abstract Number: 1114 • 2014 ACR/ARHP Annual Meeting
Clinical Effectiveness of Exercise and Corticosteroid Injection for Subacromial Impingement Syndrome: A Randomised Controlled Trial
Edward Roddy¹, Reuben Ogollah¹, Irena Zwierska¹, Praveen Datta², Alison Hall¹, Elaine Hay¹, Sue Jackson², Martyn Lewis¹, Julie Shufflebotham³, Kay Stevenson², Danielle van der Windt¹, Julie Young¹ and Nadine Foster¹, ¹Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom, ²University Hospital of North Staffordshire, Stoke-on-Trent, United Kingdom, ³Staffordshire and Stoke-on-Trent Partnership Trust, Stoke-on-Trent, United Kingdom
Background/Purpose: Subacromial impingement syndrome (SIS) is the most common cause of shoulder pain. It is commonly managed by exercise and corticosteroid injection yet how these…
Abstract Number: 1025 • 2014 ACR/ARHP Annual Meeting
Leptin Production By Osteoarthritis Synovial Fibroblasts: Stimulation By Glucocorticoids and Mineralocorticoids through the Glucocorticoid Receptor and GILZ (Glucocorticoid-Induced Leucine Zipper) Protein
Olivier Malaise¹, Biserka Relic¹, Sophie Neuville², Edith Charlier¹, Dominique de Seny¹ and Michel G. Malaise¹, ¹Department of Rheumatology, GIGA Research - University of Liège - CHU of Liège, Liège, Belgium, ²GIGA Research - University of Liège - CHU of Liège, Liège, Belgium
Background/Purpose: Osteoarthritis (OA) is a metabolic disorder for which leptin is playing a catabolic role on cartilage. In mice, obesity due to impaired leptin did…
Abstract Number: 803 • 2014 ACR/ARHP Annual Meeting
Corticosteroid-Related Adverse Events in Patients with Giant Cell Arteritis: A Claims-Based Analysis
Gordon H. Sun¹, Khaled Sarsour², Eunice Chang¹, Michael S. Broder¹, Neil Collinson³, Katie Tuckwell³, Pavel Napalkov² and Micki Klearman², ¹Partnership for Health Analytic Research, LLC, Beverly Hills, CA, ²Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, ³Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose Giant cell arteritis (GCA) is an inflammatory vasculitis preferentially affecting large and medium-sized arteries with an incidence of 1 to 30/100,000. High-dose oral corticosteroids…
Abstract Number: 492 • 2014 ACR/ARHP Annual Meeting
Patient-Reported Outcomes from a Canadian Study of Patients Taking Methotrexate and Etanercept
J. Carter Thorne¹, Edward C. Keystone², Janet E. Pope³, Melanie Poulin-Costello⁴, Krystene Phan-Chronis⁵ and Boulos Haraoui⁶, ¹Southlake Regional Health Centre, Newmarket, ON, Canada, ²Medicine, University of Toronto, Toronto, ON, Canada, ³St Joseph Health Care, London, ON, Canada, ⁴Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, ⁵Amgen Canada Inc., Mississauga, ON, Canada, ⁶Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose: The Canadian Methotrexate and Etanercept Outcome Study (CAMEO) evaluated etanercept (ETN) monotherapy vs ETN plus methotrexate (MTX) in biologic-naïve patients with rheumatoid arthritis…
Abstract Number: 295 • 2014 ACR/ARHP Annual Meeting
Intra-Articular Corticosteroid Injections in Juvenile Idiopathic Arthritis: Results from a UK Prospective Collaborative Study
Eileen Baildam¹, Roberto Carrasco², Susannah Holt³, Helen Foster⁴, Lucy R. Wedderburn⁵, Alice Chieng⁶, Joyce Davidson⁷, Yiannis Ioannou⁸, Kimme L. Hyrich⁹ and Wendy Thomson¹⁰, ¹Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ²Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Paediatric Palliative Care, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ⁴Newcastle University Medical School, Professor of Paediatric Rheumatology, Newcastle Upon Tyne, United Kingdom, ⁵Arthritis Research UK Centre for Adolescent Rheumatology,, UCL, UCLH, GOSH NHS Trust, London, United Kingdom, ⁶Paediatric Rheumatology, Royal Manchester Children's Hospital, Manchester, United Kingdom, ⁷Royal Hospital for Sick Children, Glasgow, United Kingdom, ⁸Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹⁰Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom
Background/Purpose Intra-articular corticosteroid injections (IACI) are a standard treatment in juvenile idiopathic arthritis (JIA). This study assessed response to IACI in a large prospective cohort…
Abstract Number: 240 • 2014 ACR/ARHP Annual Meeting
An Observational Study on the Influence of Glucocorticoid Exposure on Bone
Joseph Heath¹, Alexander Oldroyd², Maarten Boers³ and Marwan Bukhari², ¹Faculty of health and medicine, Lancaster University, Lancaster, United Kingdom, ²Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ³Dep of Epidemiology and Biostatistics, EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose It is well known that glucocorticoids are detrimental to bone health and has been postulated that their influence is more than their effect on…
Abstract Number: 2318 • 2013 ACR/ARHP Annual Meeting
Disease Activity in Moderate and Severe Rheumatoid Arthritis At Discontinuation in 10-Year Open-Label Extension Studies With Etanercept
Michael E. Weinblatt¹, Joan M. Bathon², Michele Hooper³, Bojena Bitman⁴, Yue Yang⁵, David H. Collier⁶, James Chung⁷ and Mark C. Genovese⁸, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Amgen Global Safety, Amgen Inc., Thousand Oaks, CA, ⁴Amgen, Inc., San Francisco, CA, ⁵Assent Consulting, South San Francisco, CA, ⁶Amgen Inc., Thousand Oaks, CA, ⁷Amgen, Thousand Oaks, CA, ⁸Division of Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Retention rates may be used as a surrogate of long-term effectiveness of drug therapy in open-label studies. Studies have reported that patients (pts)…
Abstract Number: 1052 • 2013 ACR/ARHP Annual Meeting
Glucocorticosteroids and Mortality Risk In Rheumatoid Arthritis – Results Of a Population Based Study
Diane Lacaille¹, J. Antonio Avina-Zubieta^2,3, Eric C. Sayre², Michal Abrahamowicz⁴ and John Esdaile^1,5, ¹Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁵Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Glucocorticosteroids (GC) are frequently used in the management of rheumatoid arthritis (RA). Due to their metabolic and immunosuppressive effects, they could increase the risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].